|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Medco Health Solutions Inc was a winner within the wholesale industry, rising $5.19 (11.1%) to $52.13 on heavy volume.
Pfizer Inc. (NYSE: PFE) announced today that it has established a research collaboration with Medco Health Solutions, Inc.
A health care holding provides reassurance, and we're adding to our stake in a precious-metals ETF.
Medco Health Solutions' CEO Discusses Q3 2011 Results - Earnings Call Transcript
Express Scripts expects to keep 95 percent of prescriptions without Walgreen; 3Q profit grows
Yahoo! shareholders may be hoping antitrust regulators are willing to wage war on Google's online ad dominance.
Medco Health Solutions Inc was a winner within the wholesale industry, rising 98 cents (2%) to $49.07 on light volume.
Medco Health Solutions Inc was a winner within the wholesale industry, rising 85 cents (1.8%) to $48.09 on light volume.
An agreement between two companies for retail pharmacy access helps the prospects of this stock.
Medco Health Solutions Inc was a winner within the wholesale industry, rising $1.21 (2.5%) to $49.68 on light volume.
Medco Health Solutions Inc was a winner within the wholesale industry, rising $3.26 (7.2%) to $48.92 on average volume.
Express Scripts and Medco jump as 2012-2014 estimates surpass Wall Street estimates
With bad news out of the way, we continue to stick with this stock through the broader downturn.
Compared with last year, the deals market slowed significantly In the third quarter between July and September.
Medco Health Solutions Inc was a winner within the wholesale industry, rising 41 cents (0.9%) to $46.05 on light volume.
Quarterly data released by Dealogic shows M&A and IPO markets slowed considerably in the third quarter.
The private equity giant is taking a big bite of commercial real estate tied to the grocery business.
The Foster's announcement, along with regulatory reviews, will dominate the M&A news for Wednesday.
This health care holding and this tech have unresolved issues that put pressure on their stock prices.
We'll trim this health care position on strength and look to buy some other names.
That's how you have to look at Broadcom's monster bid for NetLogic Microsytems.
One name remains a favorite, but we are considering using the other two to upgrade the portfolio.
Juniper's estimates and price target are cut at UBS, Nokia's estimates are raised at Oppenheimer through 2012 and Medco's estimates are lowered at JMP Securities.
Even without a deal with a major pharmacy chain, we like it as a standalone stock.
A chemical company and a prescription benefit company on our to-buy list hit the right levels.
US stocks rise after Google's $12.5B purchase highlights another round of corporate deals
These stocks have both short-term gain catalysts and long-term growth potential.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.